As usage increases, GLP-1 driven changes will scale from the individual to the broader society
A patient sat across from me last year six weeks into semaglutide, finally feeling her appetite shift for the first time in years and asked me something I hear in almost every follow-up: "Do I still have to watch what I eat, or does the medication handle that now?" It's a fair question
Green Tea Extract (EGCG) EGCG (epigallocatechin-3-gallate) supports metabolism and may increase GLP-1 levels
2022: An analysis called Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system describes post-marketing adverse events for the first three years that semaglutide (Ozempic) was on the market
We hypothesise the inulin will result in greater weight loss maintenance at the 18-week follow-up in subjects with prediabetes, and will promote a reduction in ectopic fat and insulin resistance independent of weight loss assessed by using the gold-standard magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) techniques
This would result in the optimization of both, patient-related and procedural, outcomes